Skip to content
SFN info

Multisystem atrophy and Small Fiber Neuropathy (SFN)

Introduction to multisystem atrophy

Description:

Multisystem atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the autonomic system (the part of the nervous system that controls involuntary action such as blood pressure or digestion) and movement. The cause of MSA is unknown, but it’s believed to be due to the degeneration of nerve cells in specific areas of the brain. This cell damage causes problems with movement, balance, and other bodily functions.

Prevalence:

MSA is a rare condition, affecting approximately 3 to 4 people in every 100,000. It is most often diagnosed in people in their 50s and 60s.

Risk Factors:

The exact cause of MSA is unknown, and no specific risk factors have been identified. However, the disease is slightly more common in men than in women. Age is also a factor, as the disease typically affects people in their 50s and 60s.

Prognosis:

MSA is a progressive disease, meaning it tends to get worse over time. The rate of disease progression varies from person to person. Most people with MSA live 6 to 10 years after symptoms first appear. As the disease progresses, daily activities become increasingly difficult and complications such as pneumonia, heart failure, or other systemic infections can be life-threatening.

Prevention:

There are currently no known ways to prevent MSA. Because the cause of MSA is unknown, it’s not clear how to prevent the disease.

Epidemiology:

MSA affects men slightly more often than women. The disease typically starts in the 50s or 60s, but can begin at any age. The prevalence of MSA varies by region, but it is considered a rare disease worldwide. In the United States, it is estimated that MSA affects approximately 15,000 to 50,000 individuals. In Europe, the prevalence is estimated to be 3.4 cases per 100,000 individuals.

multisystem atrophy connection to Small Fiber Neuropathy (SFN)

Association:

Multisystem atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the autonomic nervous system (the part of the nervous system that controls involuntary action such as blood pressure or digestion) and movement. The association between MSA and small fiber neuropathy (SFN) is not fully understood, but several hypotheses exist:

  • Autonomic dysfunction: MSA is known to cause autonomic dysfunction, which could potentially lead to SFN. The autonomic nerves are part of the small fibers, and damage to these nerves could result in SFN.
  • Neurodegeneration: MSA is a neurodegenerative disease, and it’s possible that the same process that leads to the degeneration of neurons in MSA also affects the small fibers, leading to SFN.
  • Alpha-synuclein accumulation: MSA is characterized by the accumulation of a protein called alpha-synuclein in certain areas of the brain and nervous system. It’s possible that this accumulation could also affect the small fibers, leading to SFN.

Research Updates:

Recent research into the connection between MSA and SFN is limited. However, a 2019 study published in the journal Neurology: Clinical Practice found that SFN can be an early sign of MSA. The study found that some patients who were initially diagnosed with SFN later developed MSA. This suggests that SFN could potentially be an early marker of MSA, but more research is needed to confirm this.## Symptoms of multisystem atrophy

List of Symptoms:

Multisystem atrophy (MSA) is a neurodegenerative disorder characterized by a combination of symptoms affecting both the autonomic system and motor control. While it is not specifically linked to small fiber neuropathy (SFN), some of the symptoms can overlap. The common symptoms associated with MSA include:

  • Autonomic dysfunction: This includes orthostatic hypotension (a severe drop in blood pressure upon standing), urinary incontinence, and constipation.
  • Motor control issues: These can manifest as poor coordination, slow movement (bradykinesia), muscle rigidity, and tremors.
  • Speech problems: Individuals may have slurred speech or difficulty swallowing.
  • Sleep disturbances: This can include sleep apnea and REM sleep behavior disorder, where individuals act out their dreams.
  • Vision problems: These can include blurred vision and difficulty controlling eye movements.
  • Breathing problems: Some people may experience difficulty breathing, especially when lying down.

Severity:

The severity of symptoms in MSA can vary widely among individuals. Some people may experience only mild symptoms initially, while others may have severe symptoms from the outset. Over time, symptoms typically progress and become more severe. Autonomic symptoms like orthostatic hypotension can be particularly debilitating, as they can lead to fainting spells and falls. Motor symptoms can also become severe, leading to significant disability and requiring the use of a wheelchair.

Onset:

The symptoms of MSA typically appear in adulthood, usually in the 50s or 60s. Early symptoms may be non-specific and can include urinary incontinence, erectile dysfunction in men, and a mild degree of motor impairment. As the disease progresses, more specific symptoms such as orthostatic hypotension, worsening motor control, and speech problems become apparent. Late-stage symptoms can include severe motor impairment, difficulty swallowing, and breathing problems.## Diagnosis of multisystem atrophy

Diagnosis of Multisystem Atrophy

Methods:

Diagnosing multisystem atrophy (MSA) can be challenging due to its overlap in symptoms with other neurodegenerative diseases. However, there are several methods and tests that physicians may use:

  • Neurological Examination: This involves a comprehensive assessment of the patient’s motor and sensory systems, balance, coordination, reflexes, and other aspects of neurological function. The physician will look for signs of parkinsonism (slowness of movement, rigidity, and tremor), cerebellar ataxia (unsteady gait and coordination problems), and autonomic failure (problems with blood pressure control, bladder function, and sexual function).

  • Autonomic Function Tests: These tests measure the body’s automatic functions, such as blood pressure, heart rate, sweating, and bowel and bladder function. In MSA, these functions are often impaired.

  • Imaging Tests: Magnetic resonance imaging (MRI) or computed tomography (CT) scans can help rule out other causes of the symptoms. In some cases, they may show characteristic changes in the brain associated with MSA, such as atrophy in the cerebellum or pons.

  • Sleep Studies: Sleep disorders, particularly REM sleep behavior disorder, are common in MSA and can help support the diagnosis.

Differential Diagnosis:

Several conditions can mimic the symptoms of MSA and may be considered in the differential diagnosis:

  • Parkinson’s Disease: Like MSA, Parkinson’s disease involves parkinsonism. However, the symptoms of Parkinson’s typically respond well to levodopa therapy, while those of MSA often do not.

  • Pure Autonomic Failure: This condition involves autonomic dysfunction but without the motor symptoms seen in MSA.

  • Cerebellar Ataxia: This can cause balance and coordination problems similar to those in MSA, but without the autonomic dysfunction.

  • Multiple System Atrophy with predominantly Parkinsonian features (MSA-P) and Multiple System Atrophy with predominantly Cerebellar features (MSA-C): These are subtypes of MSA that may be considered in the differential diagnosis.

Limitations:

There are several challenges and limitations in diagnosing MSA:

  • Overlap of Symptoms: The symptoms of MSA overlap with those of several other neurodegenerative diseases, making it difficult to distinguish between them based solely on clinical features.

  • Lack of Definitive Tests: There are no definitive tests for MSA. The diagnosis is primarily clinical, based on the patient’s symptoms and the results of neurological and autonomic function tests.

  • Variable Presentation: The symptoms and their progression can vary widely from person to person, adding to the difficulty of diagnosis.

  • Late-stage Diagnosis: Often, a definitive diagnosis of MSA can only be made in the late stages of the disease or post-mortem, when the characteristic pathological changes in the brain can be seen.

Treatments for multisystem atrophy

Treatments for Multisystem Atrophy

Multisystem atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the autonomic system (the part of the nervous system that controls involuntary action such as blood pressure or digestion) and movement. There is currently no cure for MSA, and no known way to prevent the disease from getting worse. The goal of treatment is to manage symptoms.

  • Medications: Various medications can be used to help manage the symptoms of MSA. These include medications to help control blood pressure, bladder problems, and movement problems. In some cases, medications used to treat Parkinson’s disease, such as levodopa, may be used, although these are often less effective in MSA patients.

  • Physical Therapy: Physical therapy can help manage some of the physical symptoms of MSA. This might include exercises to improve strength and flexibility, balance exercises, and training in how to use mobility aids.

  • Speech Therapy: Speech therapy may be beneficial for people with MSA who have difficulty speaking or swallowing.

  • Occupational Therapy: Occupational therapy can help people with MSA maintain their independence by teaching them new ways of performing daily tasks.

Effectiveness

The effectiveness of treatments for MSA varies widely and depends on the individual’s symptoms and their overall health. Medications can often help manage specific symptoms, but they do not slow the progression of the disease. Therapies such as physical, speech, and occupational therapy can help improve quality of life and maintain independence, but they also do not slow disease progression.

Side Effects

The side effects of treatment for MSA depend on the specific treatment being used. Medications can have side effects such as nausea, dizziness, and increased risk of infections. Physical, speech, and occupational therapy are generally safe, but can sometimes cause fatigue or muscle soreness.

Recent Advancements

Research into treatments for MSA is ongoing. Recent advancements include the use of stem cell therapy and gene therapy, although these are still in the experimental stages. Some studies are also looking at the use of medications that can help protect the nerve cells in the brain from damage, but these are also still in the early stages of research.